We had the pleasure of welcoming our long-term partner Beckman Coulter Diagnostics this week for valuable discussions on the continued sales and market development for our IRMA and ELISA portfolio. Their strong market presence and ability to effectively navigate a...
In the beginning of May, IDL Diagnostics team visited our distributors in Indonesia and the Philippines as part of our ongoing efforts to strengthen local partnerships and stay closely connected to our markets. During our time in Jakarta, we had an in-depth discussion...
In the interview, Gustav Sten talks about his new role, his journey within the company, and reflects on the development under Anders Hultman’s leadership. He also shares his priorities going forward, with a focus on commercialization and continued growth.
IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the position on May 28, immediately following the Annual General Meeting, succeeding Anders Hultman. Gustav Sten...
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q1’26 results – May 13, 2026 Q1 Interview: Redeye talks with CEO Anders Hultman
On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here
During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...
Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...
IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research. A big thank you to everyone we met at EAU26! We...
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q4’25 results – February 26, 2026 Q4 Interview: Redeye talks with CEO Anders Hultman
